Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals positive developments, such as a potential expansion of the Chugai partnership and increased cash reserves. Despite regulatory and strategic risks, cost containment has improved financial health, reducing net losses. The Q&A highlights the RaniPill's potential in the obesity market, with promising Phase I study outcomes that could enhance partnerships. These factors suggest a positive stock price movement, although competitive pressures and execution risks remain.
Key Financial Performance
Cash, cash equivalents, and marketable securities $49.7 million as of December 31, 2025, compared to $27.6 million at year-end 2024, reflecting an increase due to a $60.3 million private placement and upfront license payment from the Chugai collaboration agreement.
Contract revenue $1.5 million for Q4 2025 and $1.6 million for the full year 2025, compared to $1.0 million in 2024. The increase is attributed to the Chugai license and collaboration agreement.
Research and development expenses $4.9 million for Q4 2025 and $20.2 million for the full year 2025, compared to $6.8 million for Q4 2024 and $26.7 million for the full year 2024. The $6.5 million year-over-year decrease reflects cost containment measures, including pausing and terminating certain R&D programs and reducing compensation.
General and administrative expenses $5.1 million for Q4 2025 and $19.7 million for the full year 2025, compared to $5.5 million for Q4 2024 and $23.9 million for the full year 2024. The $4.2 million year-over-year decrease is due to cost containment measures, including reduced employee compensation.
Net losses $9.1 million for Q4 2025 and $41 million for the full year 2025, compared to $15.7 million for Q4 2024 and $56.6 million for the full year 2024. The decrease reflects reduced expenses and cost containment measures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
RaniPill Platform: Advanced and validated across multiple therapeutic modalities, enabling oral delivery of biologics and other therapies as an alternative to subcutaneous injections or intravenous infusions.
RT-114: Initiated Phase I clinical trial in December 2025 to evaluate safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics. Demonstrated 111% relative bioavailability compared to subcutaneous PG-102 in preclinical data.
RT-116: Reported preclinical data demonstrating comparable bioavailability, pharmacokinetics, and weight loss relative to subcutaneous semaglutide. Well tolerated with no serious adverse events observed.
Chugai Pharmaceuticals Partnership: Entered into a collaboration and licensing agreement worth up to $1.1 billion, focusing on developing oral therapy combining RaniPill with Chugai's rare disease antibody. Includes an option to expand collaboration to up to 5 additional drug targets.
Financial Position: Strengthened through a $60.3 million private placement and upfront license payment from Chugai agreement. Projected cash runway extended into Q4 2027.
Cost Containment Measures: Implemented measures leading to reduced R&D and G&A expenses, including temporary pause of certain R&D programs and reduction in employee compensation.
Strategic Shift to Obesity Market: Focused on leveraging RaniPill for oral obesity therapies, addressing tolerability challenges and high discontinuation rates associated with current injectable treatments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Risks: The company acknowledges risks related to product development and clinical trials, including uncertainties in achieving desired safety, tolerability, and bioavailability outcomes for therapies delivered via the RaniPill platform.
Strategic Execution Risks: There are risks associated with the execution of strategic partnerships, such as the collaboration with Chugai Pharmaceuticals, including the potential failure to meet performance obligations or achieve milestone payments.
Financial Risks: Despite improved financial positioning, the company faces risks related to its reliance on projected cash runway and the need for additional financing if operations extend beyond the fourth quarter of 2027.
Market and Competitive Risks: The rapidly evolving obesity treatment landscape presents competitive pressures, with existing therapies demonstrating strong efficacy. The company must differentiate its RaniPill platform to compete effectively.
Operational Risks: Cost containment measures, including temporary pauses and terminations of R&D programs, may impact the pace of innovation and development. Additionally, the company has reduced employee compensation, which could affect talent retention and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Projected Cash Runway: The company expects its existing cash, cash equivalents, and marketable securities, including expected milestone payments under the Chugai agreement, to fund operations into the fourth quarter of 2027 without the need for additional financing.
RT-114 Clinical Development: The company initiated a Phase I clinical trial of RT-114 in December 2025 to evaluate safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics across single and multiple doses. This marks an important phase for the RaniPill platform in advancing oral obesity therapies.
RT-116 Preclinical Data: Preclinical data for RT-116, an oral semaglutide delivered via RaniPill, demonstrated comparable bioavailability, pharmacokinetics, and weight loss relative to subcutaneous semaglutide. The company plans to continue advancing this program.
Chugai Collaboration Expansion Potential: The collaboration with Chugai Pharmaceuticals includes an option to expand the partnership to up to five additional drug targets under similar terms, highlighting the scalability of the RaniPill platform.
Obesity Market Opportunity: The company sees a significant opportunity in the obesity market, with the RaniPill platform potentially offering a differentiated approach by enabling oral delivery of biologics, addressing tolerability challenges, and reducing high discontinuation rates associated with current therapies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On RT-114, will weight loss data be presented, or should we focus on bioavailability data and compare it to PG-102?
A:Weight loss is one of the endpoints in the Phase Ib study, which is an 8-week study in obese patients. The data will be compared to historical data for PG-102 to assess weight loss trajectory.
Q:Given the potential tolerability of RT-114, will additional doses be explored, and will they be equivalent to PG-102?
A:The focus is on tolerability rather than maximizing weight loss to avoid issues like nausea or vomiting. Higher doses may be considered depending on the Phase Ib data, but the primary differentiation factor is tolerability.
Q:What is the importance of the Phase I study for RT-114, and what new questions should we look for answers to?
A:The study is significant as it is the first PD study with the RaniPill in humans. It aims to demonstrate weight loss data comparable to subcutaneous delivery in canines. Success could validate the RaniPill platform's broad applicability across therapeutic areas.
Q:Is the Phase I study for RT-114 a key item for partnering efforts with Chugai or other pharma partners?
A:Positive PD data from the study could be a derisking event for partnering discussions. However, decisions on exercising options with Chugai depend on their internal decision-making.
Q:Review of Unclear Management Responses
A:Management avoided directly commenting on Chugai's decision-making process for exercising options, stating it is within Chugai's discretion and did not provide specific details on their thinking.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Avenue
Officer result
PG
ProGen
RD program
RT clinic
Therapeutics
amount
area
bioavailability pharmacokinetics
cash runway
collaboration agreement
confidence
contract
decrease cost
delivery biologics
end
evaluation service
license collaboration
milestone payment
momentum
obligation
partnership
period decrease
phase
placement debt
position
program RT
progress RaniPill
reduction
release Form
safety tolerability
semaglutide
study safety
therapy RaniPill
tolerability bioavailability
value
RANI Transcript
Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript
Positive3-26
The earnings call reveals positive developments, such as a potential expansion of the Chugai partnership and increased cash reserves. Despite regulatory and strategic risks, cost containment has improved financial health, reducing net losses. The Q&A highlights the RaniPill's potential in the obesity market, with promising Phase I study outcomes that could enhance partnerships. These factors suggest a positive stock price movement, although competitive pressures and execution risks remain.
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript
Unknown4-1
The earnings call reveals significant challenges: a decrease in cash reserves, operational cost constraints, and an impairment loss. The lack of a share repurchase program and competitive pressures also weigh negatively. While there is interest in the RaniPill and a focus on RT-114, the lack of clear guidance on costs and capital constraints suggest potential struggles. The overall sentiment from the Q&A is cautious, with concerns about financial health and competitive positioning. These factors suggest a negative stock price movement in the short term.
Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript
Unknown3-31
The earnings call summary indicates several concerns: a significant net loss, regulatory and competitive pressures, supply chain challenges, and decreased cash reserves. The Q&A section revealed unclear management responses, especially regarding cost management and prioritization, which could worry investors. Despite some cost reductions and a slight revenue increase, the lack of a share repurchase program and impairment losses further contribute to a negative outlook. These factors suggest a negative stock price reaction over the next two weeks.
Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript
Unknown3-31
The earnings call reveals significant challenges, including financial losses, regulatory risks, competitive pressures, and supply chain issues. Despite reduced expenses and some revenue growth, the absence of a shareholder return plan and unclear management responses in the Q&A heighten concerns. The lack of new partnerships or positive financial guidance, coupled with impairment losses and a decreased cash position, further contribute to a negative sentiment. Without market cap data, the prediction leans towards a negative reaction, potentially between -2% to -8%.
RANI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
